Genesystem진시스템
363250 · KOSDAQ · ₩363250 · 진시스템
₩4,115▼ ₩5 (0.12%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩381M | ₩1.2B | ₩897M | ₩3.7B | ₩13B |
| Cost of sales | ₩2.8B | ₩3B | ₩2.5B | ₩2.5B | ₩4.6B |
| Gross profit | −₩2.5B | −₩1.8B | −₩1.6B | ₩1.2B | ₩8.7B |
| Operating income | −₩9.7B | −₩10B | −₩9.5B | −₩6.6B | ₩2.3B |
| Net income | −₩15B | −₩9.5B | −₩8.1B | −₩9B | ₩3.6B |
| Net income to shareholders | −₩12B | −₩8.9B | −₩7.9B | −₩9B | ₩3.6B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩14B | ₩30B | ₩39B | ₩41B | ₩51B |
| Current assets | ₩2.7B | ₩10B | ₩21B | ₩30B | ₩42B |
| Cash and equivalents | ₩1.1B | ₩5.6B | ₩9.1B | ₩17B | ₩26B |
| Total liabilities | ₩6.6B | ₩8B | ₩8.2B | ₩6.1B | ₩6.6B |
| Current liabilities | ₩2.5B | ₩2.5B | ₩2.4B | ₩2B | ₩2.6B |
| Borrowings | ₩3.7B | ₩4B | ₩4.3B | ₩3.9B | ₩3.9B |
| Total equity | ₩7.7B | ₩22B | ₩31B | ₩35B | ₩44B |
| Shareholders' equity | ₩7.9B | ₩19B | ₩27B | ₩35B | ₩44B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩6.9B | −₩7.3B | −₩7.8B | −₩6.4B | ₩986M |
| Capital spending | ₩220M | ₩259M | ₩363M | ₩238M | ₩324M |
| Free cash flow | −₩7.1B | −₩7.6B | −₩8.2B | −₩6.7B | ₩662M |
Consolidated where available. Amounts in won.
Also known as: Genesystem / 진시스템 / 363250 / KRX:363250
Source: KRX statistical information